In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

At Merck, Business Development As Usual?

Executive Summary

Merck's newly appointed SVP for world-wide licensing, C. David Nicholson, outlines the Big Pharma's dealmaking priorities at Elsevier Business Intelligence's February BIO-Windhover Pharmaceutical Strategic Outlook meeting.

You may also be interested in...



Merck Adds Flagship To Its Venture Fund Network

Merck contributes to Flagship’s latest fund, both sides promise to share ideas and expertise, but Merck gets no special rights to companies or products in Flagship’s portfolio.

Meet Merck’s Dealmaker: A Conversation With Roger Pomerantz

Merck’s new head of worldwide licensing and knowledge management Roger Pomerantz, MD, talks with IN VIVO about Merck’s business development strategy, whether biotech passion can exist on a Big Pharma scale, and the art of the deal.

Merck’s Capital Idea: Pharma’s Latest Attempt to Get Closer to VCs

Competition for biotech’s most eligible assets has never been stronger. As such, some pharmas are trying harder than ever to get in on the ground floor.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV003453

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel